Dermatitis, Atopic (ATOD)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Dermatitis, Atopic

MalaCards integrated aliases for Dermatitis, Atopic:

Name: Dermatitis, Atopic 56 6 43 39 71
Atopic Dermatitis 12 74 25 36 15 32
Atopic Eczema 12 25 15 17
Dermatitis, Atopic, Susceptibility to, 1 56 29 13
Atopic Neurodermatitis 12
Dermatitis, Atopic 1 56
Allergic Dermatitis 12
Besnier's Prurigo 12
Dermatitis Atopic 54
Eczema, Atopic 56
Eczema 71
Atod 56



food intolerance
diagnosis requires 3 major features (a positive family history is also considered a major feature) and at least 3 minor features

autosomal dominant


dermatitis, atopic:
Inheritance autosomal dominant inheritance


Summaries for Dermatitis, Atopic

Genetics Home Reference : 25 Atopic dermatitis (also known as atopic eczema) is a disorder characterized by inflammation of the skin (dermatitis). The condition usually begins in early infancy, and it often disappears before adolescence. However, in some affected individuals the condition continues into adulthood; in others, it does not begin until adulthood. Hallmarks of atopic dermatitis include dry, itchy skin and red rashes that come and go. The rashes can occur on any part of the body, although the pattern tends to be different at different ages. In affected infants, the rashes commonly occur on the face, scalp, hands, and feet. In children, the rashes are usually found in the bend of the elbows and knees and on the front of the neck. In adolescents and adults, the rashes typically occur on the wrists, ankles, and eyelids in addition to the bend of the elbows and knees. Scratching the itchy skin can lead to oozing and crusting of the rashes and thickening and hardening (lichenification) of the skin. The itchiness can be so severe as to disturb sleep and impair a person's quality of life. The word "atopic" indicates an association with allergies. While atopic dermatitis is not always due to an allergic reaction, it is commonly associated with other allergic disorders: up to 60 percent of people with atopic dermatitis develop asthma or hay fever (allergic rhinitis) later in life, and up to 30 percent have food allergies. Atopic dermatitis is often the beginning of a series of allergic disorders, referred to as the "atopic march." Development of these disorders typically follows a pattern, beginning with atopic dermatitis, followed by food allergies, then hay fever, and finally asthma. However, not all individuals with atopic dermatitis will progress through the atopic march, and not all individuals with one allergic disease will develop others. Individuals with atopic dermatitis have an increased risk of developing other conditions related to inflammation, such as inflammatory bowel disease, rheumatoid arthritis, and hair loss caused by a malfunctioning immune reaction (alopecia areata). They also have an increased risk of having a behavioral or psychiatric disorder, such as attention-deficit/hyperactivity disorder (ADHD) or depression. In a particular subset of individuals with atopic dermatitis, the immune system is unable to protect the body from foreign invaders such as bacteria and fungi (which is known as immunodeficiency). These individuals are prone to recurrent infections. Most also have other allergic disorders, such as asthma, hay fever, and food allergies. Atopic dermatitis can also be a feature of separate disorders that have a number of signs and symptoms, which can include skin abnormalities and immunodeficiency. Some such disorders are Netherton syndrome; immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome; and severe dermatitis, multiple allergies, metabolic wasting (SAM) syndrome.

MalaCards based summary : Dermatitis, Atopic, also known as atopic dermatitis, is related to dermatitis, atopic, 3 and asthma, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis, Atopic is FLG (Filaggrin), and among its related pathways/superpathways are Th17 cell differentiation and JAK-STAT signaling pathway. The drugs Clobetasol and Mineral oil have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are cataract and ichthyosis

Disease Ontology : 12 A dermatitis that is a chronically relapsing inflammatory allergic response located in the skin that causes itching and flaking.

OMIM : 56 Atopic dermatitis (ATOD), also known as eczema, is a common chronic pruritic inflammatory skin disease with a strong genetic component. Onset typically occurs during the first 2 years of life (review by Soderhall et al., 2007). (603165)

KEGG : 36 Atopic dermatitis (AD) is a relapsing chronic inflammatory skin disease characterized by eczematous skin lesions and intense pruritus. A genetic defect in the filaggrin (FLG) protein and/or environmental factors are thought to cause AD by disrupting the epidermis. This disruption, in turn, results in contact between immune cells in the dermis and antigens from the external environment leading to intense itching, scratching, and inflammation. Apart from FLG, recent genome-wide association studies (GWASs) have identified many susceptibility loci of atopic dermatitis with genome-wide significance.

Wikipedia : 74 Atopic dermatitis (AD), also known as atopic eczema, is a long-term type of inflammation of the skin... more...

Related Diseases for Dermatitis, Atopic

Diseases in the Dermatitis, Atopic family:

Dermatitis, Atopic, 2 Dermatitis, Atopic, 3
Dermatitis, Atopic, 4 Dermatitis, Atopic, 5
Dermatitis, Atopic, 6 Dermatitis, Atopic, 7
Dermatitis, Atopic, 8 Dermatitis, Atopic, 9

Diseases related to Dermatitis, Atopic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 799)
# Related Disease Score Top Affiliating Genes
1 dermatitis, atopic, 3 35.2 TSLP FLG ATOD3
2 asthma 34.3 TSLP STAT1 RNASE3 MIR155 IL4R IL4
3 egg allergy 34.0 TSLP IL4 IL13 IGHE FLG
4 hyper ige syndrome 33.9 IL4R IL4 IL13 IGHE
5 dermatitis 33.6 TSLP IL4 IL31 IL13 IGHE FLG
6 skin disease 32.7 RNASE3 MIR155 IL4 IL31 IL13 FLG
7 rhinitis 32.4 TSLP RNASE3 IL4R IL4 IL13 IGHE
8 allergic rhinitis 32.3 RNASE3 IL4R IL4 IL13 IGHE CCL17
9 allergic conjunctivitis 32.2 RNASE3 IL4 IL13 IGHE
10 bronchitis 32.1 STAT1 RNASE3 IL4 IL13 IGHE
11 food allergy 32.1 RNASE3 IL4R IL4 IL13 IGHE FLG
12 alopecia areata 32.1 IL4 IL13 FLG
13 allergic hypersensitivity disease 32.0 TSLP RNASE3 IL4R IL4 IL13 IGHE
14 contact dermatitis 31.9 IL4 IL31 FLG CCL27 CCL17
15 allergic contact dermatitis 31.9 IL4 IL31 FLG CCL27 CCL17
16 atopic keratoconjunctivitis 31.8 RNASE3 IL4 IGHE
17 bullous pemphigoid 31.8 RNASE3 IL4 IL31 IL13 IGHE CCL17
18 hypereosinophilic syndrome 31.8 RNASE3 IL4 IL13 IGHE CCL17
19 ige responsiveness, atopic 31.7 RNASE3 IL4R IL4 IL13 IGHE
20 otitis media 31.7 RNASE3 IL4 IL13 IGHE
21 respiratory failure 31.6 RNASE3 IL13 IGHE CCL17
22 respiratory allergy 31.6 TSLP RNASE3 IL4R IL4 IL13 CCL17
23 urticaria 31.6 RNASE3 IL4 IL31 IL13 IGHE CMA1
24 latex allergy 31.6 RNASE3 IL4 IL13 IGHE FLG
25 mastocytosis 31.6 IL4 IL31 IL13
26 bronchiolitis 31.6 RNASE3 IL4R IL4 IL13
27 irritant dermatitis 31.5 TSLP IL4 IL31 FLG
28 pollen allergy 31.5 RNASE3 IL4R IL13 IGHE
29 chronic conjunctivitis 31.5 TSLP RNASE3 IL4 IL13 IGHE CMA1
30 parasitic helminthiasis infectious disease 31.5 TSLP RNASE3 IL4R IL4 IL13 CCL27
31 peanut allergy 31.5 IL4 IL13 IGHE FLG CCL17
32 neurodermatitis 31.4 IL4 FLG
33 vernal keratoconjunctivitis 31.4 RNASE3 IL4 IL13 IGHE
34 schistosomiasis 31.4 RNASE3 IL4 IL13 IGHE
35 onchocerciasis 31.4 RNASE3 IL4 IL13 IGHE
36 conjunctival disease 31.4 TSLP RNASE3 IL4 IL13
37 proteasome-associated autoinflammatory syndrome 1 31.4 STAT1 RNASE3 IL4 IL13
38 allergic asthma 31.3 TSLP RNASE3 IL4R IL4 IL13 IGHE
39 gastroenteritis 31.3 TSLP RNASE3 IL4
40 psoriasis 31.2 MIR155 IL4 IL31 IL13 FLG CCL27
41 esophagitis, eosinophilic, 1 31.2 TSLP RNASE3 IL4 IL13 FLG
42 conjunctivitis 31.2 RNASE3 IL4 IL13 IGHE
43 keratoconjunctivitis 31.2 TSLP RNASE3 IL4 IL13
44 esophagitis 31.2 TSLP IL4 IL13
45 milk allergy 31.2 RNASE3 IL4 IL13 IGHE
46 common cold 31.1 TSLP RNASE3 IL4 IL13
47 tinea corporis 31.1 IL31 FLG
48 vernal conjunctivitis 31.1 RNASE3 IL4 IGHE
49 eczema herpeticum 31.1 TSLP IL4 FLG
50 chronic rhinitis 31.1 RNASE3 IL4 IL13

Graphical network of the top 20 diseases related to Dermatitis, Atopic:

Diseases related to Dermatitis, Atopic

Symptoms & Phenotypes for Dermatitis, Atopic

Human phenotypes related to Dermatitis, Atopic:

31 (show all 18)
# Description HPO Frequency HPO Source Accession
1 cataract 31 HP:0000518
2 ichthyosis 31 HP:0008064
3 abnormality of metabolism/homeostasis 31 HP:0001939
4 dry skin 31 HP:0000958
5 pruritus 31 HP:0000989
6 pallor 31 HP:0000980
7 asthma 31 HP:0002099
8 conjunctivitis 31 HP:0000509
9 eczema 31 HP:0000964
10 keratoconus 31 HP:0000563
11 recurrent skin infections 31 HP:0001581
12 atopic dermatitis 31 HP:0001047
13 food intolerance 31 HP:0012537
14 infra-orbital fold 31 HP:0011232
15 facial erythema 31 HP:0001041
16 allergic rhinitis 31 HP:0003193
17 keratosis pilaris 31 HP:0032152
18 flexural lichenification 31 HP:0007453

Symptoms via clinical synopsis from OMIM:

Skin Nails Hair Skin:
facial erythema
keratosis pilaris
pruritus (major feature)
Head And Neck Nose:
allergic rhinitis

elevated ige

Head And Neck Eyes:
cataracts (anterior- subcapsular)
conjunctivitis (recurrent)
orbital darkening

Respiratory Airways:
bronchial asthma

Laboratory Abnormalities:
immediate (type i) skin test reactivity

Clinical features from OMIM:


UMLS symptoms related to Dermatitis, Atopic:

pruritus, exanthema

Drugs & Therapeutics for Dermatitis, Atopic

Drugs for Dermatitis, Atopic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 425)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
Coal tar Approved Phase 4 8007-45-2
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
5 Parthenolide Approved, Investigational Phase 4 20554-84-1
Bronopol Approved Phase 4 52-51-7
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
Glycerol Approved, Investigational Phase 4 56-81-5 753
carbamide peroxide Approved Phase 4 124-43-6
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Montelukast Approved Phase 4 158966-92-8 5281040
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
Levocetirizine Approved Phase 4 130018-77-8 1549000
Desoximetasone Approved Phase 4 382-67-2 5311067
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
Omalizumab Approved, Investigational Phase 4 242138-07-4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
35 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
Methylprednisolone aceponate Approved, Vet_approved Phase 4 86401-95-8
Ustekinumab Approved, Investigational Phase 4 815610-63-0
39 Vedolizumab Approved Phase 4 943609-66-3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
Alitretinoin Approved, Investigational Phase 4 5300-03-8 449171 444795
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
Chitosan Experimental Phase 4 9012-76-4 71853
Cortisone Experimental Phase 4 53-06-5 222786
BCG vaccine Investigational Phase 4
49 Halometasone Experimental Phase 4 50629-82-8
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7

Interventional clinical trials:

(show top 50) (show all 1174)
# Name Status NCT ID Phase Drugs
1 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
2 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
3 A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis Unknown status NCT03461302 Phase 4 Topical coal tar;Topical corticosteroids
4 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
5 The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers: A Randomized Controlled Trial. Unknown status NCT03021161 Phase 4 Probiotic Formula
6 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
7 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
8 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
9 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
10 Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
11 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
12 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
13 Prednisolone vs. Ciclosporine in Severe Atopic Eczema Completed NCT00445081 Phase 4 Prednisolone;Ciclosporine A
14 A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis Completed NCT00484003 Phase 4 Pimecrolimus cream 1%
15 A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
16 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
17 A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment Completed NCT00673725 Phase 4 Locobase® REPAIR
18 Non-comparative Open-label Study to Investigate the Efficacy, Safety and Systemic Exposure of Pimecrolimus in Adult and Pediatric Patients With Moderate to Severe Atopic Dermatitis Treated Topically for 8.5 Days With Pimecrolimus Cream 1% Under Occlusion Completed NCT00925730 Phase 4 Pimecrolimus
19 The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema Completed NCT02300701 Phase 4 Xolair;Placebo
20 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo
21 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Completed NCT00150059 Phase 4 Pimecrolimus Cream 1%
22 Control of Therapy With Elidel vs Placebo in Patients With Atopic Dermatitis Using Bioengineering Methods Completed NCT00180141 Phase 4 Elidel-Creme
23 Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
24 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Moderate to Severe Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
25 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
26 A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis Completed NCT00510003 Phase 4 Pimecrolimus
27 An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis. Completed NCT00822783 Phase 4 Omalizumab;Placebo
28 A Multicenter, Randomized, Double-blind Clinical Study to Examine the Efficacy and Safety of Zarzenda in Comparison to Elidel in the Management of Mild to Moderate Atopic Dermatitis in Children and Adolescents Completed NCT00568412 Phase 4 Elidel
29 An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
30 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
31 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
32 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus;Pimecrolimus
33 Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis Completed NCT00130364 Phase 4 Pimecrolimus;Placebo
34 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
35 Comparative, Multicentre, Randomized, Double-blind Study to Assess the Efficacy of Tacrolimus 0.1% Ointment Versus Fluticasone 0.005% Ointment in Adult Patients Suffering From Moderate to Severe Atopic Dermatitis and Presenting With So-called 'Red Face' Lesions of the Head and Neck. Completed NCT00690105 Phase 4 tacrolimus 0.1%;fluticasone 0.005 %
36 Comparative, Multicentre, Randomised, Double-blind Study to Assess the Efficacy of Tacrolimus 0.03% Ointment Versus Fluticasone 0.005% Ointment in Children Aged 2 Years or Over Suffering From Moderate to Severe Atopic Dermatitis. Completed NCT00689832 Phase 4 Tacrolimus 0.03%;Fluticasone 0.005%
37 Quality of Life Study in Adults With Facial Eczema Completed NCT00120302 Phase 4 Pimecrolimus;Placebo
38 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
39 A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
40 An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Completed NCT01049243 Phase 4 Fluocinonide Cream 0.1%
41 Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis Completed NCT01148667 Phase 4
42 Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing Effect of Epiceram™ Device vs Standard of Care Therapy of Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) in Treatment of Atopic Dermatitis in Pediatric Subjects Completed NCT00616538 Phase 4 Fluticasone Propionate 0.05%
43 Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study Completed NCT00884325 Phase 4 Levocetirizine dihydrochloride (Xyzal);placebo
44 Phase IV - Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application Completed NCT01063218 Phase 4
45 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
46 A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis Completed NCT00828412 Phase 4 Desonide Cream 0.05%
47 Short Term Growth in Children With Atopic Dermatitis Completed NCT00236106 Phase 4 tacrolimus ointment 0.1%;mometasone furoate 0.1%
48 Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Completed NCT01177566 Phase 4 pimecrolimus
49 Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study Completed NCT02589392 Phase 4
50 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%

Search NIH Clinical Center for Dermatitis, Atopic

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
Doxepin Hydrochloride
Fluocinolone Acetonide
Methdilazine hydrochloride
trimeprazine tartrate
Triprolidine Hydrochloride
Zinc Oxide

Cochrane evidence based reviews: dermatitis, atopic

Genetic Tests for Dermatitis, Atopic

Genetic tests related to Dermatitis, Atopic:

# Genetic test Affiliating Genes
1 Dermatitis, Atopic, Susceptibility to, 1 29

Anatomical Context for Dermatitis, Atopic

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatitis, Atopic:


MalaCards organs/tissues related to Dermatitis, Atopic:

Skin, Testes, T Cells, Colon, Monocytes, Breast, Eye

Publications for Dermatitis, Atopic

Articles related to Dermatitis, Atopic:

(show top 50) (show all 20565)
# Title Authors PMID Year
A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis. 56 54 61
17441792 2007
A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. 54 56 61
11101848 2000
Linkage of atopic dermatitis to chromosomes 4q22, 3p24 and 3q21. 61 56
19517137 2009
Atopic dermatitis. 56 61
18385500 2008
Variants in a novel epidermal collagen gene (COL29A1) are associated with atopic dermatitis. 61 56
17850181 2007
Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. 61 56
12045207 2002
Linkage and association to candidate regions in Swedish atopic dermatitis families. 56 61
11511916 2001
Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. 56 61
11279517 2001
Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. 61 56
11069631 2000
MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. 46 61
20673989 2010
Mosaic atopic eczema cured by autotransplantation? 56
9752825 1998
The prevalence of childhood atopic eczema in a general population. 56
8277028 1994
Aetiology of asthma: lessons from lung transplantation. 56
8098790 1993
Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. 56
3059190 1988
Changes in the reported prevalence of childhood eczema since the 1939-45 war. 56
6150286 1984
The lines of Blaschko: a review and reconsideration: Observations of the cause of certain unusual linear conditions of the skin. 56
788770 1976
Sphingosylphosphorylcholine down-regulates filaggrin gene transcription through NOX5-based NADPH oxidase and cyclooxygenase-2 in human keratinocytes. 54 61
20230798 2010
Thymic stromal lymphopoietin receptor-mediated IL-6 and CC/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1/2, p38, and JNK) and STAT3 pathways. 61 54
20483734 2010
[Safety of azathioprine therapy adjusted to thiopurine methyltransferase activity in the treatment of infantile atopic dermatitis. Report on 7 cases]. 61 54
20525484 2010
Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. 54 61
20466416 2010
Impact of heat-inactivated Lactobacillus casei and Lactobacillus paracasei strains on cytokine responses in whole blood cell cultures of children with atopic dermatitis. 61 54
20526842 2010
Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. 54 61
20304960 2010
Analysis of four prevalent filaggrin mutations (R501X, 2282del4, R2447X and S3247X) in Austrian and German patients with atopic dermatitis. 54 61
19874431 2010
Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. 54 61
20335530 2010
Definition and characterization of an inhibitor for interleukin-31. 54 61
20335179 2010
The role of thymic stromal lymphopoietin in allergic inflammation and chronic obstructive pulmonary disease. 61 54
20143171 2010
[Atopic dermatitis - current insights into path physiology and management]. 61 54
20336617 2010
Sensing the outside world: TSLP regulates barrier immunity. 61 54
20300138 2010
Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. 61 54
20107184 2010
Association of single nucleotide polymorphisms in the IL-12 (IL-12A and B) and IL-12 receptor (IL-12Rbeta1 and beta2) genes and gene-gene interactions with atopic dermatitis in Koreans. 54 61
20060272 2010
Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. 54 61
20444170 2010
Effects of transmembrane and juxtamembrane domains on proliferative ability of TSLP receptor. 61 54
20096461 2010
Genetics of allergic disease. 61 54
20176270 2010
Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during the first 2 yr of life. 61 54
19552791 2010
Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells. 61 54
20083663 2010
Increase effect of transforming growth factor on eotaxin production by normal cultured dermal fibroblasts stimulated with interleukin-4: inhibitory effect of suplatast tosilate on eotaxin production. 61 54
20136617 2010
Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. 54 61
20030614 2010
Locus 1q21 Gene expression changes in atopic dermatitis skin lesions: deregulation of small proline-rich region 1A. 54 61
19672094 2010
Thymic stromal lymphopoietin. 54 61
20146705 2010
Human defensins and LL-37 in mucosal immunity. 61 54
19808939 2010
What is really in control of skin immunity: lymphocytes, dendritic cells, or keratinocytes? facts and controversies. 61 54
20082953 2010
Association of single nucleotide polymorphism of interleukin-18 with atopic dermatitis. 54 61
19453784 2010
Inflammatory cytokine tumor necrosis factor-alpha enhances nerve growth factor production in human keratinocytes, HaCaT cells. 54 61
19942804 2009
Increased pachyonychia congenita severity in patients with concurrent keratin and filaggrin mutations. 61 54
19785597 2009
Novel CC chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice. 61 54
19818758 2009
Brain-derived neurotrophic factor gene polymorphisms and serum levels in Chinese atopic dermatitis patients. 61 54
19522715 2009
Impaired TLR-2 expression and TLR-2-mediated cytokine secretion in macrophages from patients with atopic dermatitis. 61 54
19392987 2009
AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. 61 54
19876791 2009
[The influence of the total immunoglobulin E level concentration in serum on the results of atopy patch tests in adult patients with atopic dermatitis]. 54 61
19928660 2009
Role of the epidermal barrier in atopic dermatitis. 54 61
19682176 2009

Variations for Dermatitis, Atopic

ClinVar genetic disease variations for Dermatitis, Atopic:

6 (show all 12) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1):c.821G>A (p.Arg274Gln)SNV Pathogenic 30085 rs387906760 2:191859910-191859910 2:190995184-190995184
2 46;XX;t(7;13)(p13;q34)dnTranslocation Pathogenic 267841
3 46;XY;t(2;17)(p25;q23)dnTranslocation Pathogenic 268017
4 FLG NM_002016.1(FLG):c.1501C>T (p.Arg501Ter)SNV Pathogenic/Likely pathogenic 16319 rs61816761 1:152285861-152285861 1:152313385-152313385
5 KCNJ11 NM_000525.3(KCNJ11):c.185C>G (p.Thr62Arg)SNV Likely pathogenic 373928 rs1057518775 11:17409454-17409454 11:17387907-17387907
6 46;X;t(X;12)(p11.2;q24.33)dnTranslocation Likely pathogenic 267860
7 46;XY;t(16;20)(q23.1;p11.22)Translocation Uncertain significance 267924
8 46;XY;t(1;4)(q32;q11)Translocation Uncertain significance 268019
9 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His)SNV Uncertain significance 335760 rs143981573 2:31562482-31562482 2:31339616-31339616
10 CYP4F22 NM_173483.4(CYP4F22):c.1211T>C (p.Leu404Pro)SNV Uncertain significance 523566 rs1555730246 19:15658993-15658993 19:15548182-15548182
11 CYP4F22 NM_173483.4(CYP4F22):c.1544G>T (p.Arg515Leu)SNV Uncertain significance 523567 rs1425964436 19:15662230-15662230 19:15551419-15551419
12 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu)SNV Uncertain significance 598996 rs1558697792 2:31602803-31602803 2:31379937-31379937

Expression for Dermatitis, Atopic

Search GEO for disease gene expression data for Dermatitis, Atopic.

Pathways for Dermatitis, Atopic

Pathways related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
Show member pathways
12.38 STAT1 IL4R IL4 IL13
Show member pathways
12.16 TSLP STAT1 IL4R IL4 IL13
Show member pathways
Show member pathways
11.84 STAT1 IL4R IL4
Show member pathways
11.65 STAT1 IL4R IL4
6 11.58 STAT1 IL4 IL13
7 11.56 TSLP IL4 IL13
8 11.41 STAT1 IL4R IL4 IL13 IGHE
9 11.38 IL4 IL13 CMA1
10 11.36 IL4R IL4 IGHE CCL17
11 11 TSLP IL4 IL13
12 10.75 IL4R IL4
13 10.68 IL4R IL4 IL31 IL13 CCL17
14 10.41 IL4R IL4 IL13

GO Terms for Dermatitis, Atopic

Cellular components related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TSLP RNASE3 IL4R IL4 IL31 IL13
2 extracellular space GO:0005615 9.32 TSLP RNASE3 MIR155 IL4R IL4 IL31

Biological processes related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.73 IL4R IL4 IL13 IGHE CCL27 CCL17
2 positive regulation of cold-induced thermogenesis GO:0120162 9.7 IL4R IL4 IL13
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.63 TSLP IL4 IL13
4 positive regulation of myoblast fusion GO:1901741 9.54 IL4R IL4
5 dendritic cell differentiation GO:0097028 9.51 MIR155 IL4
6 macrophage activation GO:0042116 9.49 IL4 IL13
7 positive regulation of interleukin-10 secretion GO:2001181 9.48 IL4 IL13
8 positive regulation of interleukin-13 production GO:0032736 9.43 TSLP IL4
9 positive regulation of immunoglobulin production GO:0002639 9.4 IL4R IL13
10 positive regulation of mononuclear cell migration GO:0071677 9.37 IL4 CCL27
11 positive regulation of macrophage activation GO:0043032 9.33 MIR155 IL4R IL13
12 negative regulation of complement-dependent cytotoxicity GO:1903660 9.32 IL4 IL13
13 positive regulation of mast cell degranulation GO:0043306 9.13 IL4R IL4 IL13
14 cytokine-mediated signaling pathway GO:0019221 9.1 STAT1 IL4R IL4 IL31 IL13 IGHE

Molecular functions related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.13 IL4 IL31 IL13
2 cytokine activity GO:0005125 9.1 TSLP IL4 IL31 IL13 CCL27 CCL17

Sources for Dermatitis, Atopic

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....